Aligos Therapeutics Inc

Aligos Therapeutics Inc maintains a strong liquidity position, with $45.08 million in cash and equivalents, and a current ratio of 4.23, indicating a robust ability to meet short-term obligations. The company's liquidity_fpt score reflects a low risk of liquidity stress, supported by a low debt-to-equity ratio of 0.0 and minimal long-term debt of $207,000. However, the company reported negative operating cash flow of $42.24 million, which may signal ongoing operational challenges. Profitability metrics show mixed results. The company reported a net income of $5.06 million, but this was offset by an operating loss of $26.41 million, indicating significant operational inefficiencies. Return on equity (ROE) stands at 7.53%, and return on assets (ROA) at 4.65%, both below the industry median for biotechnology firms, suggesting underperformance relative to peers. Geographically, Aligos Therapeutics Inc does not disclose segment-specific revenue data, but its primary focus is on the development of antiviral therapies, with a concentration in HBV and HCV treatments. The company's revenue of $1.06 million is relatively modest, and there is no indication of geographic diversification in the available data. The company's growth trajectory is uncertain. While it has a positive free cash flow of $5.35 million, this is not sufficient to offset the operating cash outflow. Analysts have provided a wide range of price targets, from $20 to $175, with a mean of $65.80 and a median of $48.00, reflecting significant uncertainty about the company's future performance. The mean recommendation of 1.80 suggests a generally positive outlook, but the absence of "hold" or "sell" ratings indicates a lack of consensus. Risk factors include the company's reliance on a limited number of therapeutic candidates, which exposes it to clinical and regulatory risks. The risk assessment indicates a low probability of dilution and no immediate liquidity concerns, but the company's high operating losses and negative cash flow from operations suggest ongoing financial stress. No dilution flags were detected in recent filings, and the company has not issued new shares recently. Recent events include the continued development of its HBV and HCV programs, with no major clinical or regulatory milestones reported in the latest financial data. The company has not filed for additional financing, and there are no indications of significant changes in its capital structure or business strategy.